A carregar...
KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments
KRAS mutations in colorectal and lung cancers predict failure to respond to therapies that target the EGFR. Significant percentages of patients with KRAS wild-type tumors also fail to respond to these therapies. Relapse occurs in patients with KRAS wild-type and mutant tumors, with moderately longer...
Na minha lista:
| Publicado no: | Per Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5115778/ https://ncbi.nlm.nih.gov/pubmed/27867401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pme.13.1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|